Allianz SE Has $5.45 Million Stock Position in Elevance Health, Inc. $ELV

Allianz SE grew its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 12.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 15,535 shares of the company’s stock after acquiring an additional 1,678 shares during the quarter. Allianz SE’s holdings in Elevance Health were worth $5,446,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Rossby Financial LCC boosted its holdings in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after acquiring an additional 44 shares during the period. J.Safra Asset Management Corp bought a new stake in shares of Elevance Health in the fourth quarter worth about $32,000. ORG Partners LLC grew its position in Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after acquiring an additional 59 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Elevance Health in the fourth quarter valued at approximately $38,000. Finally, Dorato Capital Management purchased a new stake in Elevance Health during the fourth quarter worth $41,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Up 1.1%

Shares of NYSE ELV opened at $403.74 on Friday. The business has a 50-day simple moving average of $366.62 and a two-hundred day simple moving average of $344.86. The company has a market cap of $87.68 billion, a P/E ratio of 17.17, a P/E/G ratio of 2.26 and a beta of 0.67. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $426.98. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the company posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts anticipate that Elevance Health, Inc. will post 26.93 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is 29.26%.

Analyst Ratings Changes

A number of research analysts have weighed in on ELV shares. Jefferies Financial Group decreased their target price on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Bank of America increased their price target on shares of Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a research report on Thursday, June 4th. JPMorgan Chase & Co. raised their price target on shares of Elevance Health from $411.00 to $476.00 and gave the company an “overweight” rating in a report on Monday, June 8th. Leerink Partners set a $364.00 price objective on shares of Elevance Health in a report on Thursday, April 23rd. Finally, UBS Group raised their target price on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a report on Friday, May 22nd. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $416.11.

Insider Activity at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director directly owned 10,734 shares in the company, valued at $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.34% of the company’s stock.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.